APONTIS PHARMA AG (APPH) AI Stock Analysis

• Market Cap: €91.80M
• Dividend Yield: N/A
• Average Volume (3M): 1.99K
• Price to Earnings (P/E): 119.3
• Beta (1Y): 0.19
• Revenue Growth: 31.12%
• EPS Growth: N/A
• Country: DE
• Employees: 137
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 8,500,000
• 10 Day Avg. Volume: 1,124
• 30 Day Avg. Volume: 1,988
• PEG Ratio: -0.36
• Price to Book (P/B): 3.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €10.00
• Price Target Upside: -7.41% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: ―

APONTIS PHARMA AG shows a solid financial foundation with strong revenue growth and equity stability. However, its potential is hampered by low profitability and high valuation. The stock's technical indicators show moderate upward momentum, but the high P/E ratio and lack of dividend yield suggest caution is warranted.

APONTIS PHARMA AG Business Overview & Revenue Model

Company Description

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.

How the Company Makes Money

APONTIS PHARMA AG generates revenue primarily through the sale of its Single Pill products to healthcare providers, pharmacies, and through partnerships with other pharmaceutical companies. The company's revenue model relies on its ability to develop effective combination therapies that are patented and marketed under its brand. Additionally, APONTIS PHARMA engages in strategic partnerships with other pharmaceutical firms to expand its product offerings and reach. Significant factors contributing to its earnings include the company's focus on chronic disease treatments, the growing demand for simplified medication regimens, and the proprietary nature of its Single Pill formulations.

APONTIS PHARMA AG Financial Statement Overview

Summary

APONTIS PHARMA AG demonstrates solid revenue growth and a strong equity base, reflecting a stable financial position. However, low net profitability and missing cash flow data present challenges. The company's financial health could benefit from improved profit margins and consistent cash flow reporting.

Income Statement

The company showed a positive revenue growth rate of 31% from 2023 to 2024, indicating strong sales momentum. Gross profit margin improved to 57.1% in 2024, highlighting cost efficiency. However, the net profit margin is low at 1.6%, and EBIT margin data is unavailable, pointing to potential profitability issues.

Balance Sheet

The company has a strong equity ratio of 69.9% in 2024, indicating financial stability. However, the return on equity is modest at 2.4%, suggesting room for improvement in generating shareholder returns. The absence of debt in recent years reduces financial risk.

Cash Flow

Operating cash flow data is missing for 2024, limiting full analysis. The company's free cash flow was not reported, creating uncertainty about cash generation efficiency. Historical trends show fluctuating cash flows, raising concerns about cash flow stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.63M	48.47M	36.96M	55.73M	51.18M	39.24M
Gross Profit	798.74K	27.70M	23.17M	34.99M	33.79M	25.03M
EBITDA	-7.09M	3.56M	-12.94M	5.67M	1.99M	1.04M
Net Income	-7.08M	753.57K	-11.30M	2.69M	―	―
Balance Sheet
Total Assets	54.13M	44.37M	57.46M	59.85M	54.13M	29.69M
Cash, Cash Equivalents and Short-Term Investments	29.84M	15.45M	26.82M	36.35M	29.84M	8.06M
Total Debt	0.00	0.00	6.02M	0.00	0.00	0.00
Total Liabilities	13.42M	13.36M	27.20M	18.29M	13.42M	26.23M
Stockholders Equity	40.71M	31.02M	30.26M	41.57M	40.71M	3.46M
Cash Flow
Free Cash Flow	-9.97M	―	―	7.74M	1.77M	721.45K
Operating Cash Flow	-7.34M	―	-12.60M	11.02M	3.43M	1.45M
Investing Cash Flow	-2.68M	―	-2.90M	―	―	―
Financing Cash Flow	-126.87K	―	6.00M	―	20.12M	―

APONTIS PHARMA AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:APPH, the sentiment is Negative. The current price of 10.8 is below the 20-day moving average (MA) of 10.84, below the 50-day MA of 11.16, and above the 200-day MA of 10.66, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 39.95 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:APPH.

APONTIS PHARMA AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APPH	58 Neutral	€91.80M	119.34	2.46%	―	31.12%	―
Sector *	46 Neutral	C$200.02M	-3.36	-23.14%	1.86%	20.75%	-0.36%
0RAR	―	€348.27M	21.74	6.73%	2.09%	―	―
MEDOF	―	$368.80M	22.89	2.99%	―	―	―
PSG	75 Outperform	€340.80M	16.95	48.46%	1.80%	13.80%	10.94%
93M1	72 Outperform	€81.56M	2.55	12.12%	6.30%	-15.43%	8.45%
M12	68 Neutral	€254.77M	15.80	14.61%	3.67%	7.23%	58.37%